Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
Open Access
- 7 November 2022
- journal article
- research article
- Published by KEAI Publishing in Virologica Sinica
- Vol. 37 (6) , 783-785
Abstract
• Viral lineages that escape antibodies have changed the landscape of the pandemic. • SARS-CoV-2 specific T cells effectively protect against disease development. • Vaccine efficacy should be evaluated by its ability to protect from severe disease. • Inactivated SARS-CoV-2 vaccine induces a multi-protein specific T cell response. • The superior breadth of the vaccine T cell response could be a protective asset.Keywords
Funding Information
- Ministry of Health -Singapore
- National Medical Research Council (MOH-StaR17Nov-0001)
This publication has 26 references indexed in Scilit:
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 MonthsNew England Journal of Medicine, 2021
- China’s COVID vaccines have been crucial — now immunity is waningNature, 2021
- COVID-19, the first pandemic in the post-genomic eraCurrent Opinion in Virology, 2021
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in ChileNew England Journal of Medicine, 2021
- Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19The Lancet Microbe, 2021
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infectionScience, 2021
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controlsNature, 2020
- Airway Memory CD4 + T Cells Mediate Protective Immunity against Emerging Respiratory CoronavirusesImmunity, 2016
- Memory CD4+ T cells protect against influenza through multiple synergizing mechanismsJournal of Clinical Investigation, 2012
- Virus-specific CD4+ T cells: ready for direct attackJournal of Experimental Medicine, 2006